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Abstract
Background: Soluble fibrin (sFn) is a marker for disseminated intravascular coagulation and may
have prognostic significance, especially in metastasis. However, a role for sFn in the etiology of
metastatic cancer growth has not been extensively studied. We have reported that sFn cross-linked
platelet binding to tumor cells via the major platelet fibrin receptor αIIbβ3, and tumor cell CD54
(ICAM-1), which is the receptor for two of the leukocyte β2 integrins (αLβ2 and aMβ2). We
hypothesized that sFn may also affect leukocyte adherence, recognition, and killing of tumor cells.
Furthermore, in a rat experimental metastasis model sFn pre-treatment of tumor cells enhanced
metastasis by over 60% compared to untreated cells. Other studies have shown that fibrin(ogen)
binds to the monocyte integrin αMβ2. This study therefore sought to investigate the effect of sFn
on β2 integrin mediated monocyte adherence and killing of tumor cells.
Methods: The role of sFn in monocyte adherence and cytotoxicity against tumor cells was initially
studied using static microplate adherence and cytotoxicity assays, and under physiologically
relevant flow conditions in a microscope perfusion incubator system. Blocking studies were
performed using monoclonal antibodies specific for β2 integrins and CD54, and specific peptides
which inhibit sFn binding to these receptors.
Results: Enhancement of monocyte/tumor cell adherence was observed when only one cell type
was bound to sFn, but profound inhibition was observed when sFn was bound to both monocytes
and tumor cells. This effect was also reflected in the pattern of monocyte cytotoxicity. Studies using
monoclonal blocking antibodies and specific blocking peptides (which did not affect normal
coagulation) showed that the predominant mechanism of fibrin inhibition is via its binding to αMβ2
on monocytes, and to CD54 on both leukocytes and tumor cells.
Conclusion: sFn inhibits monocyte adherence and cytotoxicity of tumor cells by blocking αLβ2
and αMβ2 binding to tumor cell CD54. These results demonstrate that sFn is immunosuppressive
and may be directly involved in the etiology of metastasis. Use of specific peptides also inhibited
this effect without affecting coagulation, suggesting their possible use as novel therapeutic agents in
cancer metastasis.
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Background
A relationship between cancer and abnormalities of the
coagulation system has been recognized for over 100
years [1]. Thromboembolic disease (usually of unknown
etiology), refractory to anticoagulant therapy, may be an
early detectable sign of an underlying cancer, which could
precede the onset of observable cancer by months or
years. Although many cancer patients exhibit clinically
significant hemostatic abnormalities, about 50% of all
patients (>90% with metastases) have abnormal labora-
tory coagulation parameters [1], including soluble fibrin
(sFn) [2-4], which may also be an early marker undiag-
nosed malignancy [5]. The presence of sFn in blood has,
until recently, been considered a benign marker for the
presence of an ongoing coagulopathy. However, we have
reported a direct role for sFn in melanoma metastasis in
an experimental model [6]. Furthermore, recent reports
from in vivo studies suggest that pulmonary metastasis is
reduced in fibrinogen deficient animals [7]. Several stud-
ies suggest that sFn may be a prognostic marker in cancer
[8,9], but no clinical studies have been performed to
directly associate sFn with increased metastasis. However,
there a number of reports describing a direct clinical asso-
ciation with other coagulation proteins, including tissue
factor (TF: reviewed in [10]), Factor VIII [11], and
thrombin (reviewed in [12]).
A role for coagulation in tumor biology is further inferred
by the anti-tumor effects of anticoagulant drugs, such as
heparin, warfarinin[13] and other coumarin derivatives
[14], thrombin inhibitors [15,16], and in a number of
both experimental and spontaneous animal tumor mod-
els [17-20]. However, these therapies also increase the risk
of bleeding due to inhibition of normal clotting.
Fibrin(ogen) binds to a wide range of cellular receptors,
including two of the leukocyte β2 integrins, αMβ2 (MAC-
1) and αXβ2 (p150,95) [21], and the β2 integrin receptor,
CD54 (ICAM-1), which are important mediators of
monocyte diapedesis. Several peptides corresponding to
potential fibrin(ogen) – αMβ2 binding domains have
been identified, but the most inhibitory one reported,
designated P2C (377YKMKKTTMKIIPFNRLTIG395)[22] is
considered to be a major fibrin(ogen) γ-chain binding site
for αMβ2 and αXβ2. The major fibrin(ogen) γ-chain bind-
ing site reported on αMβ2 is in the αM  I-domain
(245KFGDPLGYEDVIPEADR261)[23]. Binding of
fibrin(ogen) to αMβ2 correlates with differentiation and is
involved in cellular signaling producing rapid perturba-
tions in cytosolic Ca2+ resulting in upregulation of αMβ2
[24]. The major fibrin(ogen) binding site on CD54 is in
the 1st  Immunoglobulin domain
(8KVILPRGGSVLVTC21)[25], which binds to the fibrino-
gen γ-chain (117NQKIVNLKEKVAQLEA133)[21]. Figure 1
is a schematic diagram showing the sequences and specif-
icities of each of these peptides on the sFn γ-chain and on
αMβ 1 and CD54.
In order for fibrin(ogen) to bind to cells it must first
undergo a conformational change to expose these sites
which may occur when fibrinogen is immobilized on
endothelial cells, resulting in enhanced monocyte adher-
ence [26]. This would augment the immune response to
inflammatory sites, since plasma fibrinogen is not adher-
ent to cells. However, in these studies, consideration was
not given to the elevated plasma levels of sFn (which is
likely to be conformationally altered) in the blood of
many patients with cancer and other conditions.
The primary hypothesis in this study was, therefore, that
sFn bound to monocytes and to tumor cells would result
in inhibition, rather than augmentation of cellular adher-
ence, and consequently cellular cytotoxicity. We further
hypothesized that blockade of sFn binding to αMβ2 and
CD54 using the above peptides would result in restora-
Schematic diagram showing the amino acid sequences, sites  of origin and effector molecules for four peptides (designated  P1 – P4) reported to inhibit fibrin(ogen) binding to αMβ2  (orange) and CD54 (blue) Figure 1
Schematic diagram showing the amino acid sequences, sites 
of origin and effector molecules for four peptides (designated 
P1 – P4) reported to inhibit fibrin(ogen) binding to αMβ2 
(orange) and CD54 (blue).Thrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
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tion of these effector functions without affecting normal
clotting.
Methods
Venepunture
Thirty milliliters of peripheral blood were drawn from
normal, healthy volunteers into 3.2% sodium citrate
vacutainers (Becton Dickinson VACUTAINER™ Systems,
Rutherford, New Jersey). Whole blood diluted by adding
20 µl of blood into 180 µl 1% crystal violet stain in 0.5%
acetic acid. A leukocyte count was performed in an
improved Neubauer counting chamber.
Venepuncture and cell isolation for this study was per-
formed in accordance with the University of Tennessee
Institutional Review Board approval (IRB# 6788B).
Preparation of Soluble Fibrin (sFn)
sFn is made in the required amount for each experiment.
To produce sFn monomer, an excess of GPRP-NH2 is
added (4 mM final). To make 1 ml of sFn solution, 50 µl
fibrinogen (10 mg/ml; plasminogen-, fibronectin-, and
factor XIII free; American Diagnostica Inc., Greenwich,
Connecticut), 84 µl of the fibrin polymerization inhibitor
Gly-Pro-Arg-Pro-amide (24 mM; GPRP-NH2; Sigma
Chemical Company), followed by 1.25 µl thrombin (100
U/ml; Sigma Chemical Company) were added to 865 µl
of RPMI 1640.
For experiments investigating peptide inhibition of sFn
binding to monocytes and tumor cells, FITC-labeled
fibrinogen (Molecular Probes, Eugene, OR) was used in
place of unlabeled fibrinogen above.
Culture of tumor cells
The A375 human amelanotic malignant melanoma cell
line was maintained in continuous cell culture. Cells were
detached from plastic using trypsin/EDTA (0.25%:
Hyclone, Logan, Utah) and washed in RPMI 1640 tissue
culture medium containing 10% fetal bovine serum (10%
FBS) centrifuged at 200 × g, resuspended in 5 ml of10%
FBS, and counted. For static adherence assays, 4 × 104 cells
were added to the wells of a 96 well flat-bottomed micro-
titer plate and incubated for 24–48 or until confluent. For
cytotoxicity experiments, cells were incubated with 5 µl of
Calcein-AM (Molecular Probes [27]) for 30 min, washed,
counted and used at appropriate concentrations in a 96
well round-bottomed plate, to which effector cells were
added. For flow experiments, the cell suspension was
added to 40 mm glass coverslips together with 10% FBS in
petri dishes and incubated until nearly confluent (24–48
h).
Isolation of mononuclear cells
Six tubes of citrated blood were diluted 1:1 with RPMI,
and 15 ml layered over 8 ml Lymphoprep™ in plastic uni-
versal containers. These discontinuous density gradients
were centrifuged for 25 min at 450 × g and the mononu-
clear cell interface removed using a sterile plastic pasteur
pipette. The cells were washed three times by resuspen-
sion and recentrifugation at 200 × g for 10 min in RPMI/
FBS so as to remove platelets. The final cell pellets were
resuspended in 10 ml RPMI. A cell count was performed
by adding 20 µl of blood into 180 µl 0.5% trypan blue
vital stain, and cells were counted in an improved Neu-
bauer counting chamber.
Purification of monocytes
Mononuclear cells obtained from the Lymphoprep™ den-
sity gradient were adjusted to 2 × 106 cells/ml, and aliq-
uots of 5 × 107 cells added to 75 cm2 serum coated tissue
culture flasks. The flasks were incubated at 37°C, in 5%
CO2, for 1.5 h in order to allow monocyte adherence to
the plastic. The non-adherent cells (lymphocytes) were
decanted. A cell count was performed on the final cell sus-
pension an aliquot were dried onto microscope slides for
analysis of cell purity. The flasks containing the remaining
adherent cells (monocytes) were rinsed twice with RPMI
and 10 ml of 3 mmol/L EDTA in RPMI/FBS added. The
flasks were then incubated at 37°C for 12 min, or until the
cells have detached from the plastic (determined by obser-
vation under an inverted microscope). The cells were
removed from the flasks using a 5 ml pipette, transferred
into universal containers, and washed three times in 10%
FBS to remove any residual EDTA. Cell purity was deter-
mined by differential counting of lymphocytes and
monocytes using May-Grunwald/Giemsa stain (Sigma). It
was important that the monocytes were used in experi-
ments immediately to avoid re-adherence to the plastic,
which would result in a decreased cell yield. In 19 experi-
ments, the mean monocyte purity was 92 ± 5%.
Preparation of soluble fibrin solution
To produce 1 mL of sFn monomer solution, 50 µl fibrin-
ogen (10 mg/ml; plasminogen-, fibronectin-, and factor
XIII free; American Diagnostica Inc., Greenwich, Con-
necticut), 84 µl of the fibrin polymerization inhibitor Gly-
Pro-Arg-Pro-amide (24 mM; GPRP-NH2; Sigma Chemical
Company), followed by 1.25 µl thrombin (100 U/ml;
Sigma Chemical Company) was added to 865 µl of RPMI
1640.
Cellular adherence assay
Tumor cells were detached from plastic using trypsin
(0.25%)/EDTA (0.1 µM) and washed in cell culture
medium. Forty thousand cells (in 200 µl 10% FBS) were
added to each well of a 96 well, flat bottomed tissue cul-
ture plate and incubated at 37°C until confluent. Six wellsThrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
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were trypsinized and the cells mixed 1:1 with Trypan blue
stain (0.5% in PBS), and counted in a hemocytometer.
The mean count was recorded. Adherent cells were left
untreated (controls) or incubated with sFn, fibrinogen
(0.5 mg/ml), GPRP-NH2 (4 mM) or thrombin (0.125 U/
ml).
After washing with RPMI, 5 µl of Calcein AM (Molecular
Probes, Eugene, OR) stock solution in DMSO were added
to 5 ml of effector cell preparation (Leukocytes; 2 × 106
cells/ml) and incubated for 30 min at 37°C. Effector cells
were left untreated (controls) or incubated with sFn or
fibrinogen (0.5 mg/ml), GPRP-NH2 (4 mM) or thrombin
(0.125 U/ml). Total fluorescence was determined by addi-
tion of 200 µl of fluorescently labeled effector cells to
three wells and fluorescence measured. Minimal fluores-
cence (blank) was measured in three wells containing
adherent cells to which only RPMI is added. After a further
wash, cells were made to 1 × 106/ml and 200 µl added to
appropriate wells, and incubated at 37°C for 1 h. The
plates were washed three times with RPMI followed by
addition of 200 µl of 0.5 M NaOH to lyse the cells. The
supernatants were removed into black 96-well microtiter
plates and fluorescence was measured on a Perkin-Elmer
Victor 3 plate reader. Specific adherence was determined
by:
(Test - Blank/Total - blank)*100%.
Antibody blocking of cellular adherence
Lyophilized murine anti-human monoclonal blocking
antibodies directed against αLβ2 (clone 25.3) and CD54
(clone 84H10) were obtained from Beckman-Coulter
(Miami, FL), as were purified immunoglobulin matched
isotypic controls (IgG1 (mouse) Clone 679.1Mc7). Block-
ing monoclonal anti-αMβ2 (clone ICRF44) was obtained
from PharMingen (BD Biosciences, San Jose, CA). All anti-
body inhibition experiments were performed using pre-
incubation of target cells with 5 µg antibody/106 cells.
Experiments were performed in triplicate wells and the
results were expressed as the mean ± SD for three separate
experiments).
Measurement of cellular cytotoxicity
Tumor cells were detached from plastic using trypsin
(0.25%)/EDTA (0.1 µM), washed and resuspended in 2
ml of culture medium and counted. Cell aliquots were
untreated or pretreated as described in the previous sec-
tion, depending on the experiment to be performed. The
cell concentration was adjusted to 1 × 105 cells/ml and
100 µl added to the wells of a round-bottomed 96 well
microtiter plate. One hundred microliters of untreated or
appropriately pre-incubated monocytes were added to the
tumor cells in appropriate wells at an effector target cell
ratios of 20:1, and the plates were centrifuged at 250 × g
for 10 min and 100 µl of supernatant carefully removed
into the appropriate wells of an optically clear 96 well flat
bottomed plate. LDH activity was measured using a stand-
ard kit. (Roche Molecular Biochemicals, Indianapolis,
Indiana). One hundred microliters of reaction mixture
were added to the wells and incubated at room tempera-
ture for 30 min in the dark. The absorbance of each well
was measured using a Perkin-Elmer Victor 3 plate reader
equipped to measure absorbance. Specific cytotoxicity
was determined by (test release- blank/total release –
blank)*100%. Initial experiments were performed to
determine the optimum time course and effector:target
(E:T) cell ratio for monocyte cytotoxicity (data not
shown). Based on these results, sFn inhibition studies
were performed using and E:T ratio of 20:1 in an 18 h
assay, which was consistent with other reports [28,29].
Monocyte adherence to tumor cells under flow conditions
To simulate the fluid shear stresses present in vivo, cover-
slips containing Calcein AM labeled, adherent A375 were
loaded into the FCS2 stage incubator (Bioptechs Inc., But-
ler, PA.) and mounted on the stage of a Leica DMIRB
inverted fluorescence microscope equipped with a Hama-
matsu Color Chilled 3CCD camera (C5810 model)
attached to a computer for data acquisition. The FCS2
incubator is a closed near-laminar flow, temperature-con-
trolled perfusion chamber which facilitates direct observa-
tion and scanning of the cells on the coverslip during
perfusion with solutions or cell suspensions. It was
designed to maintain accurate thermal control and allow
high-volume near-laminar flow perfusion. A fluid path-
way was formed (Dimensions 0.5 mm × 14 mm × 25 mm)
by separating the microaqueduct slide from the coverslip
containing cells with a single silicone gasket with a rectan-
gular bore, generating near-laminar flow conditions dur-
ing perfusion. The stage incubator was initially connected
to a peristaltic pump on the afferent side using 0.062 inch
bore S/P medical grade silicone tubing (Fisher Scientific,
Suwanee, GA), with a three way in-line tap closed to the
incubator inlet. The efferent side was connected to waste.
After connection of the electronic temperature control,
the coverslips were perfused with RPMI to briefly buffer
the cells at 37°C for fifteen minutes (flow rate of 0.5 ml/
min). The inlet was then connected to the tube containing
the appropriately treated monocyte suspension (3 mL).
The efferent tubing was also connected to the same tube,
and Di-I [30] labelled monocytes were recirculated across
the tumor cells for 1 h, after which, the tubing was set up
to the initial configuration and the cells were again
washed with RPMI for 10 min to remove unbound mono-
cytes. Individual still images in five randomly chosen
fields of view were captured and stored on the computer.
The number of monocytes (red) and tumor cells (green)
were counted in each field of view and the mean mono-
cyte/tumor cell ratio was calculated.Thrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
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The wall shear stress was calculated using the momentum
balance for a Newtonian fluid. The viscosity of water at
37°C was used as an approximation of the viscosity of the
buffer used (RPMI 1640; 0.007 poise). As described in the
following equation, the wall shear stress experienced by
the monolayer is equal to: T = 3µQ/2a2b, where T=wall
shear stress, µ= coefficient of viscosity (0.007 Poise), Q=
volumetric flow rate (0.0083 cm3/s), a= half channel
height (0.025 cm), and b=channel width (1.5 cm). The
wall shear rate is given by T/µ. Experiments were con-
ducted to maximize adherence in the model, within phys-
iologically relevant shear rates (In post-capillary venules,
shear rate has been reported to range between 35 and 560
s-1 [31,32]. This range is believed to be characteristic of the
stresses that a leukocyte must resist to form a stable adhe-
sion with a vessel wall).
Preparation of sFn blocking peptides
Based on the reported activities of the various
fibrin(ogen) blocking peptides, four were selected which
would possibly also inhibit fibrin mediated immunosup-
pression. Table 1 shows our laboratory designation, the
amino acid sequence, its molecule of origin, and which
molecule it binds to.
Stock peptides
Lyophilized peptides (50% purity) were obtained from
Sigma-Genoysys (The Woodlands, TX). Peptides 1,2, and
4 were each made up to a 100 µM stock concentration in
PBS. Peptide 3 was first solubilized in a small amount of
DMSO (on account of its hydrophobicity), followed by
subsequent suspension in PBS, and was also made up to a
100 µM stock concentration. All peptides were divided
into 50 µL aliquots, and stored at -20°C. Peptides were
used at a working concentration of 4 µM.
Effect of sFn blocking peptides on clot formation in 
purified fibrinogen and in recalcified citrated plasma
Experiments were performed to determine if the specific
fibrin(ogen) adherence inhibitors also affected 1. fibrino-
gen clotting in the presence of thrombin, or 2. normal
coagulation in re-calcified plasma.
1. Fibrinogen (0.5 mg/ml, 0.05 mmol/L), and thrombin
(0.125 U/ml) were used at the concentration demon-
strated to induce maximal inhibition of adherence and
cytotoxicity in microplate assays. Thrombin (0.625 µl
(stock 100 U/ml) was added to RPMI 1640 medium con-
taining 25 µl (stock 10 mg/ml) thrombin alone or in the
presence of 4 mmol/L specific peptide or peptide combi-
nation in a total volume of 1 ml. The tubes were left at
room temperature and clotting was determined by
observed gelation of the solution every 30 s, and the
approximate clotting time was recorded. An additional
control was also tested in which the fibrin polymerization
inhibitor GPRP-NH2 was added to fibrinogen in the pres-
ence of P1-P4 prior to thrombin addition. The tube was
left at room temperature to determine if clotting was
observed.
2. The effect of the specific peptides on the clotting of re-
calcified normal human plasma was also examined to
determine if the normal coagulation cascade was inhib-
ited in their presence. Plasma alone or in the presence of
single or combined peptides P1-P4 (4 mM final concen-
tration: 20 µl of 100 mM stock) was re-calcified with
CaCl2 (50 µL; 25 mM stock) in a final volume of 500 µL.
Tubes were left at room temperature and clotting time was
then recorded.
Peptide blocking of cellular adherence
After fluorescence labeling of each cell type, stock peptides
were added to both confluent coverslips and/or 1 millili-
ter suspensions of monocytes (P1 and P2) and/or sFn
solution (P3 and P4) for a final treatment concentration
of 4 mM (40uL added to 1 mL suspension). Cells were
treated with peptides for 20 minutes at room temperature,
followed directly by washing of cells (by centrifugation
and resuspension – monocytes, or perfusion with RPMI
1640 for 10 min – tumor cells). For sFn peptide treatment,
peptides remained in the sFn solution during incubation.
Monocyte adherence to tumor cells under flow conditions
was then performed as described above.
Peptide blocking of fluorescently labeled sFn adherence to 
A375 cells and monocytes
Oregon Green labeled fibrinogen was obtained from
Molecular Probes (Oregon Green 488 human fibrinogen
conjugate (F-7496)). Lyophilized stock fibrinogen (5 mg)
was made up in RPMI 1640 to a total volume of 5 ml, aliq-
uotted (25 µl) and stored at -20°C until time of experi-
ment. For experiments, labeled sFn was prepared as
Table 1: Designation of sFn inhibitory peptides, sequences, molecule of origin and ligand
Peptide # Sequence Molecule of Origin Ligand
P1 NNQKIVNLKEKVAQLEA sFn (g-chain) CD54 (1st Ig)
P2 YKSMKKTTMKIIPFNRLTIF sFn (g-chain) αMβ2 (αM I)
P3 KVILPRGGSVLVTC CD54 (1stIg) sFn (y-chain)
P4 KFGDPLGYEDVIPEADREG αMβ2 (αM I) sFn (g-chain)Thrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
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described for sFn above, and incubated for 20 minutes at
37°C to allow sFn formation.
Stock peptides (P1 and P2) were added to both confluent
coverslips containing unlabeled A375 cells and/or 1 mil-
liliter suspensions of unlabeled monocytes and/or labeled
sFn (P3 and P4) at a final concentration of 4 mM, for 20
minutes at room temperature, followed by washing in
RPMI 1640. Peptides were retained in the sFn solution
during adherence. Untreated or peptide pre-treated
monocytes and/or tumor cells were incubated for 20 min
with labeled-sFn (+/- peptide treatment as appropriate),
and washed in RPMI 1640. The monocyte pellet was
resuspended in 1 ml of phenol red free RPMI 1640 and 10
µl added to a microscope slide, coverslipped and sealed
for microscopy. Coverslips containing tumor cells were
inverted onto a microscope slide together with 50 µl of
Pro-long Gold™ (Molecular Probes) mounting medium,
and allowed to harden for microscopy. An Olympus BX61
was used (100× oil immersion objective) to observe sam-
ples and capture images. Using the same microscope set-
tings to observe differences in fluorescence between
samples, five representative fields were captured of each
slide for each pre-treatment. Images were processed using
Image Pro Plus™ (Media Cybernetics, Silver Spring, MD)
and deconvolved using AutoDeblur™ deconvolution soft-
ware (Media Cybernetics, Silver Spring, MD).
Statistical analysis
In static microplate adherence and cytotoxicity assays
(Figures 2, 3 and 6) each data point was obtained as the
mean +/- SD for three replicates. Each experiment was per-
formed at least three times. Student's t-test for independ-
ent (unpaired) variables was used to determine significant
differences between groups.
For experiments investigating adherence under flow con-
ditions (Figures 7 and 8), each experiment used mono-
cytes from a single individual and the experiment was
internally controlled on each occasion by inclusion of
untreated and sFn/sFn treated cells. Each experiment was
performed at least five times. Inhibition of adherence
compared to the untreated control, as well as peptide
blocking of sFn inhibition was determined by direct com-
parison with its own internal control in each experimental
protocol. Thus, the number of untreated and sFn treated
controls was greater than the number of tests for each sin-
gle or combined peptide. Since there was also variation in
monocyte adherence from individual donors, each pep-
tide effect was compared to the whole population of
either untreated or sFn treated control, using Student's t-
test for independent (unpaired) variables.
Results
Effect of sFn on monocyte/tumor cell adherence in static 
microplate assays
Experiments were performed to determine the effect of
sFn pre-incubation of either monocytes, tumor cells, or
both on monocyte adherence to A375 melanoma cells in
static microtiter plate assays (Figure 2). In the absence of
sFn, monocytes adherence was 32.9 ± 1.3%. Pre-treatment
of tumor cells with sFn significantly (P < 0.01 compared
to untreated control) increased adherence (68.5 ± 0.7%).
Addition of sFn treated monocytes to untreated tumor
cells also increased adherence (38.75 ± 1%; P < 0.05 com-
pared to untreated control), but to a significantly lower
degree than tumor cell pretreatment with sFn (P < 0.01
Effect of soluble fibrin on monocyte adherence to tumor cells Figure 2
Effect of soluble fibrin on monocyte adherence to tumor 
cells. Calcein AM labeled PBM incubated with A375 cells 
after pre-treatment of A375 and/or PBM with RPMI or sFn 
prior to assay. sFn pre-treatment of tumor cells significantly 
increased adherence to untreated A375 cells compared to 
the untreated control (P < 0.01: n = 3). Preincubation of 
monocytes also marginally increased adherence to untreated 
A375 cells (P < 0.05: n = 3) compared to the untreated con-
trol, but to a significantly lower degree than with sFn treated 
A375 cells (P < 0.01 compared to monocyte sFn). sFn pre-
treatment of both effector and target cells resulted in a sig-
nificant inhibition of adherence (P < 0.05: n = 3) compared to 
the untreated control.Thrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
Page 7 of 14
(page number not for citation purposes)
compared to sFn treated tumor cells). However, when
both monocytes and tumor cells were both pre-treated
with sFn a pronounced inhibition of adherence was
observed (15.95 + 1%; P < 0.01 compared to untreated
control).
Effect of sFn on monocyte cytotoxicity against tumor cells 
in static microplate assays
Monocyte cytotoxicity against A375 melanoma cells was
measured in a static microplate assay (Figure 3). At an
effector:target cell ratio of 20:1 monocyte cytotoxicity was
28.6 + 0.7%. Pre-treatment of A375 cells with sFn did not
significantly (P >0.05) affect cytotoxicity (27.1 + 0.7%)
compared to the untreated control, but a significant
reduction (P <0.05) was observed when monocytes were
sFn treated (20 + 0.7%). Maximal inhibition of cytotoxic-
ity compared to untreated cells was observed when both
effector and target cells were sFn treated (17.3 + 0.3%; P <
0.01 compared to Untreated control, sFn treated mono-
cytes and to sFn treated A375 cells; n = 3).
Effect of shear rate on monocyte adherence to tumor cells 
under flow conditions
Initial experiments were conducted to maximize adher-
ence in the model, within physiologically relevant shear
rates. Figure 4 shows the percentage adherence (number
of monocytes/field/number of tumor cells/field) at flow
rates of 0.5 – 2.5 ml/min. Maximal monocyte adherence
was observed at a flow rate of 0.5 ml/min corresponding
to a shear stress of 0.93 dynes/cm2, with a corresponding
shear rate of 132.9 s-1. This shear rate was within the range
of the stresses (35 and 560 s-1) [31,32] which a leukocyte
must resist to form a stable adhesion with a postcapillary
vessel wall. Experiments investigating sFn inhibition of
adherence were performed in further experiments at a
flow rate of 0.5 ml/min. Figure 5 shows two representative
images of monocytes (red) adherent to tumor cells
(green). In Figure 5A untreated monocytes were adhered
to untreated tumor cells. Less adherence was observed
when both cells were pre-treated with sFn (B).
Effect of sFn and monoclonal anti-αLβ2, αMβ2 and CD54 
on monocyte/tumor cell adherence under flow conditions
Pre-treatment of monocytes with monoclonal anti-αLβ2
antibody (5 µg/106cells) inhibited their adherence to
untreated A375 cells by 80 ± 7%. (Figure 6), whereas only
23 ± 0.3% inhibition was observed when A375 cells were
also pre-treated with sFn (P < 0.05 compared to untreated
A375 cells). Conversely, monocyte pre-treatment with
anti-αMβ2 monoclonal antibody only inhibited adher-
ence by 22.5 ± 2.6% to untreated A375 cells, and by 80 ±
0.5% to sFn pre-treated tumor cells (P < 0.05 compared to
untreated A375 cells). Incubation of A375 cells with anti-
CD54 inhibited monocyte adherence of untreated mono-
cytes by 53 ± 0.3%, and sFn pre-treated monocytes by 86
± 0.2%, which were significantly greater (P < 0.05) com-
pared to untreated monocytes). Pre-incubation of either
cell type with appropriate isotypic control or an irrelevant
antibody (CD4) did not significantly (P > 0.05) inhibit
adherence.
Effect of αMβ2 and CD54 specific blocking peptides on 
thrombin induced fibrin polymerization
Experiments were performed to determine if fibrin(ogen)
blocking peptides affected the ability of fibrinogen to clot.
Using purified fibrinogen in the absence or presence of P1
+ P2, P3 + P4, or all four peptides together, clotting was
observed within approximately 5 minutes. Addition of
Effect of sFn pre-treatment on monocyte cytotoxicity against  tumor cells Figure 3
Effect of sFn pre-treatment on monocyte cytotoxicity against 
tumor cells. Calcein AM labeled PBM incubated with A375 
cells after pre-treatment of A375 with or without sFn and 
pre-treatment of PBM with or without sFn prior to assay. sFn 
pre-treatment of monocytes was slightly inhibitory (P <0.05 
compared to untreated control; n = 3). Significantly greater 
inhibition was observed when A375 cells were sFn pre-
treated (P <0.01 compared to untreated and to monocyte 
treated cells; n = 3). Maximal inhibition of PBM cytotoxic 
activity occurred when both cell types were treated with sFn 
(P < 0.01 compared to untreated, monocyte treated or A375 
treated cells: n = 3).Thrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
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GPRP-NH2 to purified fibrinogen prior to thrombin addi-
tion failed to clot within 15 minutes, indicating the pro-
duction of soluble, rather than polymerized fibrin. Using
no treatment, or the same combinations of peptides, clot-
ting of recalcified plasma was observed under all condi-
tions in approximately 4 minutes.
Effect of sFn, αMβ2 and CD54 specific blocking peptides on 
sFn inhibition of monocyte/tumor cell adherence under 
flow conditions
Figure 7 shows the effect of two specific peptides, desig-
nated P1 and P2 on sFn inhibition of monocyte adher-
ence to A375 melanoma cells in a flowing microscope
stage incubator. P1 represents the sFn major binding site
for CD54 and P2 represents the sFn major binding site for
αMβ2. From the left, the first bar (+/+) shows the mean
(+SD) inhibition when both monocytes and tumor cells
were pre-incubated for 20 min with sFn. SFn considerably
reduced monocyte adherence (P < 0.05 compared to
untreated cells). When both monocytes (which express
αMβ2 and some CD54) and tumor cells were pre-treated
with both P1 and P2 followed by sFn prior to assay (Bar2
+P1P2/+P1/P2) sFn inhibition was considerably reduced
to a level which was not significantly different to the
untreated control, as was also observed when cells were
treated with peptides in the absence of sFn (Bar3; P1P2/
P1/P2). These results suggest that by blocking the major
receptor sites for sFn on α Mβ2 and CD54 binding of sFn
is blocked, allowing α Lβ2 (LFA1 which does not bind to
sFn) and αMβ2 to bind to CD54 restoring adherence. If
A375 cells are treated with P1 to block CD54 binding to
fibrin (even when sFn was added subsequently) and
monocytes are treated with sFn, inhibition was still
observed (Bar4; +P1/+) since CD54 was blocked by P1.
Similarly, inhibition was still observed when monocytes
were treated with P2 to block sFn binding to α Mβ2, and
tumor cells were treated with sFn (Bar 5; +/+P2). As con-
trols, tumor cells were incubated with P1 (but not sFn)
and monocytes were treated with sFn. Inhibition was still
observed because P1 blocked sFn coated α Mβ2 binding
(Bar 6; P1/+). Similarly, inhibition was observed when P2
blocked sFn binding to monocytes and tumor cells were
treated with sFn (Bar 7; +/P2). The final 3 bars (Fg/Fg, thr/
thr, GPRP-NH2/GPRP-NH2) showed that no significant
(P > 0.05 compared to untreated cell adherence) inhibi-
tion was observed when cells were treated with soluble
fibrinogen, thrombin, or GPRP-NH2). These results dem-
onstrate the peptides P1 and P2 are effective in inhibiting
sFn inhibition of monocyte adherence by a mechanism
involving its blocking of CD54 to αMβ2.
Figure 8 shows the effect of two specific peptides, desig-
nated P3 and P4 on sFn inhibition of monocyte adher-
ence to A375 melanoma cells in a flowing microscope
stage incubator. P3 represents the CD54 major binding
site for sFn and P4 represents the α Mβ2 major binding
site for sFn. From the left, the first bar (+/+) shows the
mean (+SD) when both monocytes and tumor cells were
pre-incubated for 20 min with sFn. SFn considerably
reduced monocyte adherence (P < 0.05 compared to
untreated cells). Pre-treatment with sFn with P3 and P4
prior to its incubation with tumor cells and monocytes
(which should block its binding) resulted in a marked
increase in cell adherence, which was not significantly dif-
ferent than the untreated control (Bar 2; +P3P4/+P3P4;P
< 0.05), thus reversing sFn inhibition of adherence. As
expected, addition of peptides P3 and P4 to cells did not
significantly affect adherence (Bar 3; -P3P4/-P3P4; P >
0.05 compared to untreated). When sFn was treated with
P3 and incubated with tumor cells, and monocytes were
untreated, little or no inhibition was observed, because α
Mβ2 could still bind to CD54 directly (Bar4; +P3/-). Sim-
ilarly, when sFn was pre-treated with P4 and incubated
with monocytes, and tumor cells were untreated, no inhi-
bition was observed, because tumor cells would not bind
P3-sFn, and the sFn on the monocytes could bind to
CD54 on the tumor cells (Bar 6; +P3/+). Similarly, when
sFn was pre-treated with P4 and incubated with mono-
cytes, and tumor cells were incubated with sFn, no inhibi-
tion was observed, because the free α Mβ2 could still bind
to sFn on the tumor cells (Bar 7; +/+P4).
Effect of perfusion flow rate on monocyte adherence to  tumor cells Figure 4
Effect of perfusion flow rate on monocyte adherence to 
tumor cells. Monocytes (1 × 106/ml) were perfused across a 
monolayer of A375 cells attached to a coverslip in a per-
fusion stage incubator for 1 h at 37°C, and non-adherent 
cells were washed off by perfusion to waste for 10 min. 
Monocyte adherence was maximal at a flow rate of 0.5 ml/
min, and linearly decreased as the flow rate was increased to 
1, 1.5, and 2 ml/min.Thrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
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These results show that blocking of sFn with peptides rep-
resenting its major CD54 and α Mβ2 receptor sites effec-
tively inhibited its ability to block adherence of
monocytes to tumor cells.
Effect of αMβ2 and CD54 specific blocking peptides on sFn 
adherence to monocytes and tumor cells
Having demonstrated that specific sFn blocking peptides
reversed sFn inhibition of monocyte/tumor cells adher-
ence, experiments using fluorescently labeled fibrinogen
to prepare sFn were performed to observe whether sFn
binding to cells was also decreased. After sFn binding (+/-
) peptide pre-treatment, slides were observed on an Olym-
pus BX61 fluorescence microscope equipped with an
Olympus (COOL-1300QS) digital camera for image
acquisition. Oregon Green fluorescence was detected
using a 535 nm long-pass dichroic filter. After setting up
the microscope to detect tumor cells or monocytes, all set-
tings were kept identical for subsequent slides. Figure 9
shows binding of FITC-sFn to A375 cells (A). Fluorescent
sFn bound strongly to both the cell types. However, when
tumor cells were pre-treated with P1 + P3 (B), or sFn was
pre-treated with P3 + P4 (C), almost no binding was
observed. Similarly, sFn bound strongly to monocytes
(D). Monocyte Pre-incubation with P1 + P2 considerably
reduced sFn fluorescence, as did sFn pre-incubation with
P3 + P4, demonstrating that the blocking peptides cause
reduced sFn binding to cells.
Discussion
Our results clearly demonstrate that sFn inhibits both
monocyte adherence and cytotoxicity against tumor cells.
Our previous work [33] demonstrated that sFn coated
tumor cells enhanced metastasis in an experimental
metastasis model. Further studies using monoclonal
blocking antibodies showed that sFn binds to the β2
integrin receptor, CD54, which is present on many cancer
cells. Other reports have demonstrated that fibrinogen
binds to αMβ2 on leukocytes [22,34].
In microplate monocyte/tumor cell adherence assays,
monocytes adhered to tumor cells (Figure 1). Pre-treat-
ment of tumor cells with sFn considerably enhanced
monocyte binding. This is consistent with the report by
Ugarova et al [22], showing increased monocyte binding
to fibrinogen bound endothelial cells. Indeed, this has
been postulated as a mechanism of increased immune cell
homing to inflammatory sites. A small, but non-signifi-
cant increase in monocyte adherence was also observed
when monocytes were pre-incubated with sFn. However,
monocyte adherence was inhibited by over fifty percent
when both cell types were sFn treated prior to assay. Since
Tumor cells were grown on 40 mm coverslips to confluence and labeled with Calcein AM (green) Figure 5
Tumor cells were grown on 40 mm coverslips to confluence and labeled with Calcein AM (green). Monocytes were labeled 
with DiI (C18; red), made to 1 × 106 cells/ml and continuously perfused across the tumor cells at 0.5 ml/min for 1 h. (Left) 
monocyte adherence to untreated A375 cells. (Right) monocyte (pre-treated with sFn) adherence to sFn pre-treated A375 
cells. sFn pre-treatment of both effector and target cells inhibited monocyte adherence.Thrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
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sFn levels are elevated in many cancer patients, peripheral
blood monocytes and circulating tumor cells undergoing
metastasis would likely be coated in sFn, reducing their
ability to adhere to each other.
Since adherence is a necessary step in most cytotoxic effec-
tor pathways, cellular cytotoxicity assays were performed
to determine if monocyte killing of tumor cells was simi-
larly inhibited by sFn When both cell types were
untreated, specific monocyte cytotoxicity was 28.6 ± 0.7
(Figure 3). A small, but non significant (P >0.05) inhibi-
tion was observed when monocytes were sFn pre-treated.
However, a greater inhibition (P < 0.05 compared to
untreated cells) was observed when untreated monocytes
were incubated with sFn treated tumor cells. This is inter-
esting, since increased monocyte adherence was observed
under similar conditions (Figure 1). This suggests that
although sFn bound to tumor cells increases monocyte
adherence, it may inhibit subsequent signaling to allow
delivery of the cytotoxic lethal hit to the tumor cells. Fur-
thermore, these results are consistent with our previously
published data showing increased metastasis when sFn
treated tumor cells were injected into warfarinized mice
[33]. SFn pre-treatment of both monocytes and tumor
cells resulted in the greatest inhibition of cytotoxicity (P <
0.05 compared to both untreated and sFn treated tumor
cells), which is consistent with the observed decrease in
adherence under similar conditions. Taken together, these
results would suggest that, in vivo, elevated levels of circu-
lating sFn would result in its binding to both tumor cells
and monocytes, leading to an ongoing immunosuppres-
sion.
To investigate the mechanism of sFn inhibition, mono-
clonal blocking antibodies directed against monocyte
αLβ2 and αMβ2, or tumor cell CD54 were incubated with
untreated or sFn treated monocytes and tumor cells (Fig-
ure 2). Pre-incubation of monocytes with blocking anti-
αLβ2 inhibited adherence to tumor cells by over eighty
percent. However, inhibition by anti-αLβ2 was signifi-
cantly (P < 0.01) reduced when tumor cells were sFn
treated. Conversely, monocyte pre-treatment with block-
ing anti-αMβ2 had relatively little effect on adherence to
untreated tumor cells, but significant blocking was
observed if the tumor cells were sFn treated. Although this
antibody has not been reported to block fibrin(ogen)
binding to αMβ2, it is likely since the epitope for this clone
is on the αM  I-domain, which is proximal to the
fibrin(ogen) γ-chain binding site on αM.
These data suggest that, in the absence of sFn, unstimu-
lated monocyte adherence is mediated predominantly via
αLβ 1, whereas αMβ2 seems to predominate in binding to
sFn treated tumor cells. This is consistent with previous
observations that fibrin(ogen) binds to αMβ2 [34]. These
results were further supported by the observation that pre-
treatment of tumor cells with blocking anti-CD54 inhib-
ited untreated monocyte adherence and was even more
effective in blocking adherence of sFn treated monocytes.
This observation is supported by the observations of Gar-
diner and D'Souza [35]. This clone of anti-CD54 (84H10)
inhibits both β2 integrin and fibrinogen binding to
CD54. Isotypic murine immunoglobulin isotype or an
irrelevant monoclonal antibody (anti-CD4) had no effect
on monocyte – tumor cell adherence in the presence or
absence of sFn.
Effect of monoclonal anti-αLβ2, -αMβ2 and CD54 on mono- cyte adherence to tumor cells under flow conditions in the  presence or absence of sFn Figure 6
Effect of monoclonal anti-αLβ2, -αMβ2 and CD54 on mono-
cyte adherence to tumor cells under flow conditions in the 
presence or absence of sFn. Anti-αLβ2 inhibited monocyte 
adherence to untreated cells (P <0.05; n = 3), but was signifi-
cantly (P < 0.01 compared to non-sFn treated cells; n = 3) 
less effective in blocking monocyte binding to sFn pre-treated 
tumor cells. Conversely, anti-αMβ2 inhibited monocyte 
adherence to sFn pre-treated tumor cells to a significantly (P 
< 0.01) greater extent than to untreated tumor cells. Anti-
CD54 inhibited monocyte adherence to untreated tumor 
cells by over 50%, and by over 80% when tumor cells were 
pre-incubated with sFn. Isotypic control IgGs or an irrelevant 
monoclonal antibody (CD4) did not affect monocyte adher-
ence.Thrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
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To further investigate the mechanism of sFn inhibition of
monocyte/tumor cells adherence, four peptides were cho-
sen which had previously been reported to represent
major fibrin(ogen) binding sites on CD54 (P1) and αMβ2
(P2) for fibrin(ogen), and the fibrin(ogen) γ-chain bind-
ing sites for CD54 (P3) or αMβ2 (P4). Blocking of the
fibrin(ogen) binding sites on both monocytes (αMβ2) and
tumor cells (CD54), prior to sFn treatment significantly (P
< 0.05) reduced sFn mediated inhibition of monocyte/
tumor cell adherence under flow conditions (Figure 7).
Blocking of both the CD54 and αMβ2 binding sites on sFn
again significantly (p < 0.05) reduced the ability of sFn to
inhibit monocyte adherence (Figure 8). In further experi-
ments Oregon Green-labeled sFn was incubated with
tumor cells or monocytes alone or after appropriate cell or
sFn blocking peptide treatment. Fluorescence microscopy
(using exactly the same microscope settings for all slides)
showed a considerable reduction in sFn binding to either
cell type after appropriate cell or sFn treatment with either
P1 + P2, or P3 + P4, confirming that peptide treatment
inhibits sFn binding to the cells (Figure 9). Further evi-
dence of the specificity of the blocking peptides was pro-
vided in experiments demonstrating their inability to
Effect of specific blocking peptides designated P3 (binds  CD54 binding site on sFn) and P4 (binds to αMβ2 binding site  on sFn) on sFn inhibition of monocyte/tumor cell adherence  under flow conditions Figure 8
Effect of specific blocking peptides designated P3 (binds 
CD54 binding site on sFn) and P4 (binds to αMβ2 binding site 
on sFn) on sFn inhibition of monocyte/tumor cell adherence 
under flow conditions. (from left to right): sFn treatment of 
monocytes and A375 cells (n = 25) significantly (P < 0.01 
compared to untreated control; n = 10) inhibited cell adher-
ence. Pretreatment of sFn with P3 and P4 restored cell 
adherence to levels not significantly different to the 
untreated control (P < 0.05 to fibrin; n = 5; P > 0.05 to con-
trol). Pre-treatment of tumor cells and/or monocytes with 
either P3+P4, P3 alone or P4 alone were not inhibitory (P > 
0.05; n = 5 in each case, compared to untreated control).
Effect of specific blocking peptides designated P1 (binds to  CD54) and P2 (binds to αMβ2) on sFn inhibition of mono- cyte/tumor cell adherence under flow conditions Figure 7
Effect of specific blocking peptides designated P1 (binds to 
CD54) and P2 (binds to αMβ2) on sFn inhibition of mono-
cyte/tumor cell adherence under flow conditions. (from left 
to right): sFn pre-treatment of monocytes and A375 cells (n 
= 25) significantly (P < 0.01 compared to untreated control; n 
= 30) inhibited monocyte adherence. Pretreatment of cells 
with P1 and P2 restored cell adherence to levels not signifi-
cantly different to that of the untreated control (P < 0.05 to 
fibrin (n = 10); P > 0.05 to control). Pre-treatment of tumor 
cells with P1 and monocytes with sFn or tumor cells with sFn 
and monocytes with P2 inhibited adherence to a similar level 
to that of sFn treatment of both cells (P > 0.05 to fibrin; n = 
5 in each case). Pretreatment of effector and tumor cells 
with fibrinogen (Fg), thrombin or GPRP did not significantly 
inhibit adherence (P > 0.05 compared to untreated cells; n = 
5)Thrombosis Journal 2006, 4:12 http://www.thrombosisjournal.com/content/4/1/12
Page 12 of 14
(page number not for citation purposes)
inhibit normal fibrinogen clotting in a pure system and in
recalcified plasma.
Figure 10 is a schematic diagram summarizing the results
of this study. The presence of sFn on tumor cells enhances
monocyte binding, probably by upregulating αMβ2 bind-
ing to sFn coated CD54 (B), which is consistent with our
results and with previous reports [21,22]. Pre-treatment of
monocytes (but not tumor cells) with sFn does not affect
monocyte adherence, probably because free tumor cell
CD54 is still available to bind monocyte αLβ2 (C). Pre-
treatment of both cells with sFn inhibits both αLβ2 and
αMβ2 mediated adherence (D), which is the most likely
situation in vivo, in patients with elevated levels of circu-
lating sFn.
Extrapolation of these results to the physiological setting
would suggest that, in cancer patients with elevated levels
of sFn, monocytes and circulating tumor cells would bind
sFn, resulting in the inability of monocytes to adhere to,
and kill, tumor cells, resulting in enhanced metastasis.
The use of fibrin blocking peptides may represent a novel
class of therapeutic agents to reduce sFn mediated immu-
nosuppression, and decrease metastasis in many cancers,
while avoiding the negative bleeding problems com-
monly associated with anticoagulant therapies.
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